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Abstract
Dent–Wrong disease, an X-linked recessive disorder of the proximal tubules, presents with hyper-
calciuria, nephrocalcinosis, nephrolithiasis, renal insufficiency, low-molecular-weight proteinuria,
rickets and/or osteomalacia. Dent and Friedman initially characterized the disorder in 1964 follow-
ing studies of two patients with rickets who presented with hypercalciuria, hyperphosphaturia, pro-
teinuria and aminoaciduria. Since then, extensive investigation identified two genetic mutations
(CLCN5 and OCRL1) to be associated with Dent–Wrong disease. Clinical features supported by la-
boratory findings consistent with proximal tubule dysfunction help diagnose Dent–Wrong disease.
Genetic analysis supports the diagnosis; however, these two genes can be normal in a small subset
of patients. The differential diagnosis includes other forms of the Fanconi syndrome, which can be
hereditary or acquired (e.g. those related to exposure to exogenous substances). Treatment is sup-
portive with special attention to the prevention of nephrolithiasis and treatment of hypercalciuria.
We review the rare forms of Fanconi syndromewith special attention to Dent–Wrong disease.
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Introduction
Fanconi syndrome represents a generalized dysfunction of
the proximal tubule with varying degrees of wasting of any
substance normally reclaimed by proximal tubule cells [1].
Phosphate, glucose, amino acid and bicarbonate wasting
produce clinical consequences. Children present with
rickets and impaired growth. Adults present with bone dis-
eases such as osteomalacia and osteoporosis. The clinical
constellation of symptoms includes metabolic acidosis,
hypokalemia, hypouricemia, hypophosphatemia, glyco-
suria, polyuria, sodium wasting, hypercalciuria and low-
molecular-weight (LMW) proteinuria or aminoaciduria [2].
A Swiss pediatrician, Guido Fanconi [3], described a
child who had glycosuria and albuminuria in addition to
rickets and dwarfism [4]. The syndrome bears his name.
The etiology of Fanconi syndrome is incompletely de-
fined and probably varies with each cause. Variants of
Fanconi syndrome may be inherited or acquired (Table 1).
Acquired Fanconi syndrome may occur at any age de-
pending upon the timing of exposure to noxious toxins
and drugs that injure the proximal tubule.
Genetic conditions such as Wilson disease, late-onset
forms of cystinosis and galactosemia present with Fanconi
syndrome later in life as toxic materials accumulate
over time resulting in progressive proximal renal tubular
damage [1].
Inherited causes of Fanconi syndrome include heredi-
tary fructose intolerance, Lowe syndrome and Dent–Wrong
disease [5]. Hereditary fructose intolerance results in a
deficiency of the aldolase B enzyme, which cleaves fructose
1-phosphate. After ingesting fructose, accumulation of
fructose 1-phosphate leads to sequestration of inorganic
phosphate and deficiency of adenosine triphosphate
(ATP). ATP deficiency causes impaired proximal tubular
function or Fanconi syndrome. Other associated symp-
toms include hypoglycemic shock, severe abdominal
symptoms and impaired function of the Krebs cycle that
produces metabolic acidosis and is exacerbated by im-
paired renal bicarbonate reabsorption [6].
Characteristic features of Lowe (oculocerebrorenal) syn-
drome include congenital cataracts, mental retardation,
muscular hypotonia and renal Fanconi syndrome [7]. In
contrast, Dent–Wrong disease remains confined mainly to
the kidney. Both diseases display LMW proteinuria with
varying degree of glycosuria, aminoaciduria and phospha-
turia. Proximal renal tubular acidosis may be severe in Lowe
syndrome causing growth retardation. Rickets is thought to
be a consequence of hypophosphatemia in Dent–Wrong
disease and acidosis in Lowe syndrome. Hypercalciuria, a
characteristic of Dent–Wrong disease, leads to nephrocalci-
nosis or nephrolithiasis. Renal failure progresses to end-
stage renal disease in young adulthood in Dent–Wrong
disease and earlier in patients with Lowe syndrome. Dent–
Wrong diseasewill be the focus of this review.
Dent–Wrong disease
Dent and Friedman initially described what has been
called Dent’s disease in 1964 when they reported two
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patients with rickets and urinary findings of hypercalciuria,
hyperphosphaturia, proteinuria and aminoaciduria [8].
This rare disorder affects ∼250 families. Dent–Wrong disease,
an X-linked recessive disorder of the proximal tubules, pre-
sents with clinical features of Fanconi syndrome, LMW
proteinuria, hypercalciuria with calcium nephrolithiasis,
nephrocalcinosis, hyperphosphaturia, hypophosphatemic
rickets and progressive renal failure [2, 9]. Some of the
affected individuals have mutations that inactivate a
voltage-gated chloride transporter CLC-5.
The CLC-5 transporter-affected individuals have muta-
tions in the CLCN5 gene located on chromosome Xp11.22
encoding a lysosomal transport protein, CLC-5, a voltage-
gated chloride transporter [9, 10]. CLC-5 belongs to the CLC
family of chloride transporters [5, 10, 11]. CLCN5 gene
encodes the CLC-5 chloride channel, a 746-amino acid
protein [12]. Defects in CLCN5 define Dent–Wrong disease 1.
CLC-5 co-localizes with the proton-ATPase in subapical
endosomes of the proximal tubule cells. These endosomes
process proteins that the glomeruli filter and are subse-
quently taken up by the proximal tubule through adsorp-
tive endocytosis. Proton-ATPase acidifies the endosomal
space, releasing the proteins from membrane-binding
sites and making them available for proteolytic degrad-
ation. CLC-5 mediates electrogenic exchange of chloride
for protons in these endosomes, dissipates the positive
charge generated by proton entry and may provide a
brake or set point for endosomal acidifications. Mutations
that inactivate CLC-5 interfere with the mechanism for re-
absorption of LMW proteins, thus bringing about LMW
proteinuria. Glycosuria, aminoaciduria and phosphaturia
are less consistently seen.
Mutations in the OCRL1 gene which defines Lowe syn-
drome can also induce a Dent–Wrong-like phenotype,
Type 2 Dent–Wrong disease [7, 13]. This gene has a locus
on the X chromosome, Xq25 and encodes a phosphatidyli-
nositol 4,5-bisphosphate 5-phosphatase. This phosphat-
ase sits on the trans-Golgi network in renal epithelial cells
where it directs protein to the appropriate membrane. Of
the 32 families with the clinical diagnosis of Dent–Wrong
disease, 19 had mutations in CLCN5 and 5 had mutations
in OCRL1, but the diagnosis of Lowe syndrome had been
excluded in the members of the latter families because
cataracts were absent [14]. A subset of patients with
Dent–Wrong disease do not have any mutations in either
of the above genes [14].
The CLC-5 protein and the OCRL1 phosphatase interact
with the actin cytoskeleton and participate in endosomal
apparatus assembly. Similarities in renal features of these
two syndromes may be the result of defective membrane
trafficking.
CLC-5 presents in the membrane of pre-endocytic vesi-
cles below the brush border of the proximal tubule [12]. It
facilitates the entry of Cl− that partakes in active acidifica-
tion of the vesicles by a proton pump. Lack of this
Cl− channel interferes with protein reabsorption from the
tubule through the megalin–cubilin receptor system [2].
Such a lack also leads to a disturbance of cell surface
receptor recycling via the sodium/proton exchanger NHE3,
and the sodium/phosphate transporter NPT2a. The above
abnormalities may explain phosphaturia, glycosuria and
aminoaciduria [15].
Clinical manifestations
Manifestations usually occur during childhood and those
affected present with bone pain and difficulty in walking
due to rickets, or symptoms of renal stones such as ab-
dominal pain and hematuria [2, 16]. Occasionally, patients
seek additional consultation as a result of the fortuitous
discovery of proximal tubular dysfunction, including LMW
proteinuria [17]. Symptomatic disease occurs almost ex-
clusively in males, with inheritance being X-linked reces-
sive [16].
Renal manifestations of Lowe (oculocerebrorenal) syn-
drome include those of Dent–Wrong disease. However,
patients with Lowe syndrome also have renal tubular acid-
osis, congenital cataracts and mental retardation, findings
which are absent in Dent–Wrong disease [7].
Diagnosis
The clinical diagnosis of Dent–Wrong disease requires the
presence of all three of the following criteria: (i) LMW pro-
teinuria (elevation of urinary excretion of β2-microglobulin,
Clara cell protein and/or retinol-binding protein by at least
5-fold above the upper limit of normal), (ii) hypercalciuria
(>4 mg/kg of body weight in a 24 h urine collection) and
(iii) at least one of the following: nephrocalcinosis, calcium
nephrolithiasis, hematuria, hypophosphatemia or chronic
kidney disease [16, 17]. The excretion of LMW proteins
in the urine such as albumin, β2-microglobulin and α1-
microglobulin continues to be the most reliable feature of
the disease. The degree of proteinuria remains relatively
constant, between 0.5 and 2 g/day in adults and up to
Table 1. Proximal RTAwith Fanconi Syndrome
Genetic NaPi-II co-transporter mutation
Inherited systemic disease Cystinosis
Tyrosinemia
Hereditary fructose intolerance
Galactosemia
Glycogen storage disease (Type I)
Mitochondrial disorders
Wilson’s disease
Lowe syndrome
Dent’s disease
Fanconi–Bickel syndrome
Acquired causes
Drug-induced
Nucleotide reverse
transcriptase inhibitors
Tenofovir, adefovir
Nucleoside reverse
transcriptase inhibitors
Didanosine, lamivudine, stavudine
Anticancer drugs Ifosfamide, oxaplatin, cisplatin
Anticonvulsant drugs Valproic acid
Antibiotics Aminoglycoside, expired tetracyclines
Antivirals Cidofovir
Other Streptozocin
Miscellaneous conditions
Heavy metals Lead, cadmium, mercury and copper
Vitamin D deficiency
Multiple myeloma
Amyloidosis
Renal transplantation
Paroxysmal nocturnal
hemoglobinuria
Aristolochic acid
Fumaric acid
Suramin
Paraquat
L-lysine and L-arginine
Tubulo-interstitial nephritis
Membranous nephropathy
with antitubular antibodies
Permission to reproduce table granted by Oxford University Press [1].
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1 g/day in children [2, 16, 18]. Albumin excretion represents
less than half of the proteins excreted. LMW proteinuria
does not produce any systemic symptoms whereas hyper-
calciuria can cause nephrolithiasis or nephrocalcinosis.
Hypercalciuria appears in most cases of Dent–Wrong
disease and begins in childhood. Nephrolithiasis occurs
in ∼50% of male patients. Stone constituents include
calcium phosphate or a mixture of calcium phosphate and
calcium oxalate [2]. Nephrolithiasis presents during the
teenage years. Radiological nephrocalcinosis of the me-
dullary type affects male patients and occasionally
female patients. Serum levels of 1,25-vitamin D and 25-
vitamin D remain normal.
Aminoaciduria, glycosuria, acidosis, hypokalemia and
progressive renal failure present inconsistently. End-stage
renal disease commonly arises in the fifth decade (47 ± 13
years). Renal biopsy specimens show chronic interstitial
nephritis with scattered calcium deposits [2, 16]. Promin-
ent tubular atrophy with diffuse inflammatory infiltrate
composed of lymphocytes, and foci of calcification around
and within epithelial cells can be seen. Glomeruli generally
have normal architecture but may have hyalinization.
However, a rare case of biopsy-proven focal glomerulo-
sclerosis was described [19].
The identification of a mutation in either CLCN5 or OCRL1
confirms the diagnosis. However, a minority of patients
will not have either mutation present [7]. Among those
with supportive clinical findings, a negative genetic test
does not rule out this disease.
The absence of clinical cataracts and the lack of severe
intellectual deficit are key features that make a diagnosis
of Dent–Wrong disease 2, associated with OCRL1 muta-
tions, more likely than a diagnosis of Lowe syndrome.
Males who have homozygote genes in this X-linked
disease suffer more severely. Females have mild symp-
toms but become carriers. Females transmit the disease
to half of their sons and half of their daughters will be car-
riers. All the daughters of affected males will be carriers
as they will have inherited the X chromosome harboring
the mutation. All the sons of affected fathers who have
inherited the Y chromosome and not the X chromosome,
will be normal.
Treatment
Dent–Wrong disease does not have a specific treatment.
Supportive therapy alleviates symptoms and prevents ne-
phrolithiasis. The main focus centers on calcium metabol-
ism to prevent bone disease, kidney stone formation and
nephrocalcinosis. Calcium nephrolithiasis management
includes increasing fluid intake. Dietary calcium restriction
to reduce calcium excretion may contribute to bone
disease and, therefore, should be avoided [10]. Low-dose
thiazide diuretics may decrease calciuria [20, 21]. How-
ever, since these patients waste sodium, they respond
with excessive diuresis, kaliuresis and low blood pressure
[2, 20]. Rickets in children can be cured by the administra-
tion of pharmacological doses of vitamin D. Osteomalacia
in adults can also be corrected with vitamin D treatment.
However, vitamin D supplement to treat rickets should be
used with caution since enhanced gastrointestinal ab-
sorption of calcium may exacerbate calcium excretion,
calcium nephrolithiasis and nephrocalcinosis. Monitoring
urine calcium excretion before and after vitamin D
therapy would be prudent [10].
As with any renal disease, acceleration to renal failure
can be prevented by avoiding nephrotoxic agents, extreme
high or low blood pressures and postrenal obstruction. A
future intervention may include high-dose oral citrate,
which delayed renal failure progression in a CLC-5 knockout
mouse model even in the absence of stone formation [22].
Conclusion
Dent–Wrong disease, a rare form of proximal tubular dys-
function, represents a genetically X-linked recessive in-
herited disorder with male predominance. Symptoms of
polyuria, microscopic hematuria, asymptomatic proteinuria
or kidney stones presenting in childhood lead to diagnosis.
Mutations in the CLCN5 gene located on chromosome
Xp11.22 occur in 60% of affected patients (Dent–Wrong
disease 1) and OCRL1 gene located on chromosome xq25
in 15% of patients (Dent–Wrong disease 2).
CLCN5 mutations inactivate a voltage-gated chloride
transporter that exists almost exclusively in the kidney
proximal tubule cells. It functions to acidify the endo-
somes through an ATPase pump to allow exchange of a
chloride for a proton. Inactivation of the CLC-5 leads to
generalized dysfunction of the proximal tubule. OCRL1
encodes a phosphatidylinositol bisphosphate 5-phosphat-
ase, which also affects endosomal trafficking. Lowe (ocu-
locerebrorenal) syndrome, also characterized by proximal
tubular dysfunction, has mutations in the OCRL1 gene too;
however, there is genetic heterogeneity in the type of mu-
tations. This may explain the phenotypic differences from
Dent–Wrong disease by the presence of congenital catar-
acts, mental retardation and tubular acidosis. The diagno-
sis for Dent–Wrong disease can be made clinically by the
presence of LMW proteinuria, hypercalciuria and at least
by one of the following criteria: nephrocalcinosis, nephro-
lithiasis, hematuria, hypophosphatemia or chronic kidney
disease. End-stage renal failure occurs between the third
and fifth decades of life. Demonstrating the mutations
affecting CLCN5 or OCRL1 gene confirms the diagnosis;
however, a minority of patients will have no identifiable
mutation suggesting involvement of other genes. Treat-
ment includes symptomatic relief and prevention of ne-
phrolithiasis by (i) increasing fluid intake, (ii) using thiazide
diuretics to reduce calcium excretion and (iii) careful sup-
plementing vitamin D. Dietary calcium reduction should
be avoided.
Authors’ note
The term, Dent’s disease, was coined by Professor Charles
Dent’s very good friend and mentee, Professor Oliver M.
Wrong. The latter, along with Professors AGW Norden, TG
Feest, SJ Scheinman, RV Thakker and others collaborated
to elucidate the disease in large measure. ‘We should ac-
tually call it Dent–Wrong disease’ [23], says Professor Raj
Thakker of Oxford’s Nuffield Department of Clinical Medi-
cine. After all, he points out, ‘Wrong invested even more in
its investigation than Dent himself [23]’. Many other
authors fully embraced this recommendation [24–26].
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